IDHIFA® is a prescription medicine used to treat people with acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation whose disease has come back or has not improved after previous treatment(s). It is not known if IDHIFA is safe and effective in children.
500 javax.jcr.RepositoryException: This session has been closed.
javax.jcr.RepositoryException: This session has been closed.
Cannot serve request to /content/commercial/us/idhifadtc/en/home/_jcr_content/root/experiencefragment_824236702..html/bms-commercial/components/content/general/experiencefragment on this server
Apache Sling
IDHIFA® is the first and only treatment
option for IDH2-mutated AML that has come back or not improved after previous treatment